Maxion Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Maxion Therapeutics Ltd. - overview
Established
2020
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
Founded in 2020 by its CEO, John McCafferty, and CSO, Aneesh Karatt-Vellatt, and based in Cambridge, UK, Maxion Therapeutics Ltd. , operates as a biotechnology platform that develops therapeutic drugs for chronic pain, autoimmunity, and cardiovascular disease. In March 2025, Maxion Therapeutics Ltd. raised GBP 58 million in Series A funding led by new investor General Catalyst Partners, with participation from other new investors British Patient Capital, Solasta Ventures, and Eli Lilly & Company.
Returning investor LifeArc, Monograph Capital Partners, and Business Growth Fund. The company offers therapies addressing chronic pain, autoimmunity, and cardiovascular diseases via the ion channel and GPCR-driven diseases. The company KnotBody® Technology by fusing naturally occurring cysteine-rich miniproteins (Knottins) into antibody binding loops in ion channel and GPCR drug discovery, offering superior selectivity compared to small-molecule drugs. The company plans to use the March 2025 funding to transform into a clinical-stage biotech company.
Current Investors
BGF Investment Management, Monograph Capital, LifeArc
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.maxiontherapeutics.com/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.